ELDN Stock Forecast: Eledon Pharmaceuticals, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Eledon Pharmaceuticals, Inc. is $8. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 29 of 100 as at 21 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Eledon Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (49): The share price has been relatively steady.
Value (29): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
ELDN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on ELDN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 July 2026 | Rodman & Renshaw | Initiates | Buy | $12 |
| 18 Nov 2025 | Guggenheim | Maintains | Buy | $9.00 → $8.00 |
| 2 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 25 July 2025 | Craig-Hallum | Initiates | Buy | — |
| 18 June 2025 | HC Wainwright & Co. | Assumes | Buy | $9.00 |
| 20 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 4 June 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 10 May 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 May 2024 | HC Wainwright & Co. | Maintains | Buy | — |
| 22 Mar 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 13 Nov 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 24 Oct 2023 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Sept 2023 | Noble Capital Markets | Initiates | Outperform | — |
| 22 Aug 2023 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 26 May 2023 | HC Wainwright & Co. | Reiterates | Buy | — |
| 1 June 2022 | SVB Leerink | Maintains | Outperform | — |
| 24 Nov 2021 | HC Wainwright & Co. | Maintains | Buy | — |
| 27 Apr 2021 | SVB Leerink | Maintains | Outperform | — |
| 23 Mar 2021 | Cantor Fitzgerald | Initiates | Overweight | — |
| 8 Feb 2021 | SVB Leerink | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ELDN.
This page is one stock. Monday covers all of them.
ELDN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
ELDN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Eledon Pharmaceuticals, Inc. returned +28.1% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
ELDN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- —
- Price / book
- 2.1×
- EV / EBITDA
- —
Cheaper than 42% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- —
- Net margin
- —
- Return on equity
- −105.7%
- Return on assets
- −46.1%
- Dividend yield
- —
Higher than 13% of US stocks
Higher than 9% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Eledon Pharmaceuticals, Inc. has a market value of $150.3M and an enterprise value of $81.0M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$98.6M.
Free cash flow in the twelve months to 30 June 2026: −$73.9M.
Eledon Pharmaceuticals, Inc. employs 33 people.
Data provided by Twelve Data
ELDN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at ELDN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Eledon Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about ELDN
What is the ELDN stock price forecast for 2026-2027?
The median 12-month analyst price target for Eledon Pharmaceuticals, Inc. is $8, with estimates ranging from $7 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is ELDN stock a buy right now?
Of the 6 analysts covering Eledon Pharmaceuticals, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eledon Pharmaceuticals, Inc. 29 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank ELDN?
As at 21 Nov 2026, Eledon Pharmaceuticals, Inc. ranks 29 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Volatility (49 of 100).
Will ELDN stock go up?
No one can know that. What the data says: the median 12-month target from 6 analysts is $8, and Ticker Nerd's factor model ranks Eledon Pharmaceuticals, Inc. 29 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the ELDN stock forecast for 2030?
No analyst covering Eledon Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ELDN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $12 over the next 12 months.
How has ELDN stock performed over the past year?
Eledon Pharmaceuticals, Inc. returned +28.1% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Eledon Pharmaceuticals, Inc. do?
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions. The company’s lead product candidate, tegoprubart, is an anti-CD40L antibody designed to target the CD40L pathway, which plays a central role in immune activation and transplant rejection.
About Eledon Pharmaceuticals, Inc.
Eledon Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing immune-modulating therapies for organ and cell transplantation, autoimmune disease, and neurodegenerative conditions. The company’s lead product candidate, tegoprubart, is an anti-CD40L antibody designed to target the CD40L pathway, which plays a central role in immune activation and transplant rejection. Eledon is currently advancing research programs in kidney transplantation, islet cell transplantation, xenotransplantation, and amyotrophic lateral sclerosis (ALS). Its work centers on therapies intended to protect transplanted organs, reduce rejection risk, and address serious diseases with limited treatment options. Headquartered in Irvine, California, Eledon Pharmaceuticals operates as a focused drug development company within the broader biotechnology and immunology market.
CEO Dr. David-Alexandre C. Gros M.D., Ph.D. · 33 employees · United States · https://eledon.com